New cell therapy using bone marrow-derived stem cells/endothelial progenitor cells to accelerate neovascularization in healing of experimental ulcerative colitis

Current Pharmaceutical Design

Volumn 17, Issue 16, 2011, Pages 1643-1651

  Deng, Xiaoming ^a,d   Szabo, Sandor ^a,d,e   Chen, Longchuan ^a   Paunovic, Brankica ^a   Khomenko, Tetyana ^a,d   Tolstanova, Ganna ^a,c,d,g   Tarnawski, Andrzej S ^b,f   Jones, Michael K ^c   Sandor, Zsuzsanna ^b,f  

^a Diagnostic and Molecular Medicine VALBHS   (United States)

^b Internal Medicine HCG   (United States)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^d Departments of Pathology   (United States)

^e Departments of Pharmacology   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g TARAS SHEVCHENKO NATIONAL UNIVERSITY OF KYIV   (Ukraine)

Author keywords

Angiogenesis; Bone marrow derived endothelial progenitor cells; Inflammatory bowel disease; Neovascularization; Ulcerative colitis; Vasculogenesis; Wound ulcer healing

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; BONE MARROW; BONE MARROW CELL; BONE MARROW DERIVED PROGENITOR CELL; CELL DIFFERENTIATION; CELL HYPOXIA; COLON MUCOSA; ENDOTHELIAL PROGENITOR CELL; HUMAN; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STEM CELL TRANSPLANTATION; TISSUE REGENERATION; ULCERATIVE COLITIS; WOUND HEALING;

ANIMALS; CELL TRANSPLANTATION; COLITIS, ULCERATIVE; ENDOTHELIUM, VASCULAR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RATS; WOUND HEALING;

EID: 79960019629     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796197007     Document Type: Review

References (105)

1. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961; 14: 213-22.
2. Siminovitch L, McCulloch EA, Till J E. The distribution of colonyforming cells among spleen colonies. J Cell Physiol 1963; 62: 327-36.
3. Messner HA. Stem cells: the challenge and opportunities. Bone Marrow Transplantation 2008; 42: S57-9.
4. Pontikoglou C, Deschaseaux F, Sensebé L, Papadaki HA. Bone Marrow Mesenchymal Stem Cells: Biological Properties and Their Role in Hematopoiesis and Hematopoietic Stem Cell Transplantation. Stem Cell Rev 2011; Epub ahead of print.
5. Jeong JH. Adipose stem cells and skin repair. Curr Stem Cell Res Ther 2010; 5: 137-40.
6. Witkowska-Zimny M, Walenko K. Stem cells from adipose tissue. Cell Mol Biol Lett 2011; 16: 236-57.
7. Christ B, Dollinger MM. The generation of hepatocytes from mesenchymal stem cells and engraftment into the liver. Curr Opin Organ Transplant. 2010; Epub ahead of print.
8. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. 1997; Science 275:964-7.
9. Shi Q, Rafii S, Wu MH, Wijelath ES, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998; 92: 362-7.
10. Crosby JR, Kaminski WE, Schatteman G, et al. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res 2000; 87: 728-30.
11. Zhang ZG, Zhang L, Jiang Q, Chopp M. Bone marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse. Circ Res 2002; 90: 284-8.
12. Hess DC, Hill WD, Martin-Studdard A, Carroll J, Brailer J, Carothers J. Bone marrow as a source of endothelial cells and NeuNexpressing cells after stroke. Stroke 2002; 33: 1362-8.
13. Urbich C, Heeschen C, Aicher A, et al. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2003; 108: 2511-6.
14. Quirici N, Soligo D, Caneva L, Servida F, Bossolasco P, Deliliers GL. Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells. Br J Haematol 2001; 115: 186-94.
15. Wang QR, Wang BH, Huang YH, Dai G, Li WM, Yan Q. Purification and growth of endothelial progenitor cells from murine bone marrow mononuclear cells. J Cell Biochem 2008; 103: 21-9.
16. Jujo K, Hamada H, Iwakura A, Thorne T, et al. CXCR4 blockade augments bone marrow progenitor cell recruitment to the neovasculature and reduces mortality after myocardial infarction. Proc Natl Acad Sci USA 2010; 107: 11008-13.
17. Burt RK, Craig RM, Milanetti F, Quigley K, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease:long-term follow- up. Blood 2010; 116: 6123-32.
18. Zaruba MM, Franz WM. Role of the SDF-1-CXCR4 axis in stem cell-based therapies for ischemic cardiomyopathy. Expert Opin Biol Ther 2010; 10: 321-35.
19. Zhang G, Nakamura Y, Wang X, Hu Q, Suggs LJ, Zhang J. Controlled release of stromal cell-derived factor-1alpha in situ increases c-kit+ cell homing to the infarcted heart. Tissue Eng 2007; 13: 2063-71.
20. Askari AT, Unzek S, Popovic ZB, et al. Effect of stromal-cellderived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003; 362: 697-703.
21. Frederick JR, Fitzpatrick JR 3rd, McCormick RC, et al. Stromal cell-derived factor-1alpha activation of tissue-engineered endothelial progenitor cell matrix enhances ventricular function after myocardial infarction by inducing neovasculogenesis. Circulation 2010; 122: S107-17.
22. Ceradini DJ, Gurtner GC. Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc Med 2005; 15: 57-63.
23. Lakkisto P, Kyto V, Forsten H, et al. Heme oxygenase-1 and carbon monoxide promote neovascularization after myocardial infarction by modulating the expression of HIF-1α, SDF-1α and VEGFB. Eur J Pharmacol 2010; 635: 156-64.
24. De Falco E, Avitabile D, Totta P, Straino S, et al. Altered SDF-1-mediated differentiation of bone marrow-derived endothelial progenitor cells in diabetes mellitus. J Cell Mol Med 2009; 13: 3405- 14.
25. Gallagher KA, Liu ZJ, Xiao M, et al. Diabetic impairments in NOmediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1α. J Clin Invest 2007; 117: 1249-59.
26. Westenbrink BD, Lipsic E, van der Meer P, et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007; 28: 2018-27.
27. Salcedo R, Wasserman K, Young HA, et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1α. Am J Pathol 1999; 154: 1125-35.
28. Bruno S, Bussolati B, Scacciatella P, et al. Combined administration of G-CSF and GM-CSF stimulates monocyte-derived proangiogenic cells in patients with acute myocardial infarction. Cytokine 2006; 34: 56-65.
29. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-95.
30. Djonov V, Baum O, Burri PH. Vascular remodeling by intussusceptive angiogenesis. Cell Tissue Res 2003; 314: 107-17.
31. Tepper OM, Capla JM, Galiano RD, et al. Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells. Blood 2005; 105: 1068-77.
32. Di Rocco G, Gentile A, Antonini A, et al. Enhanced healing of diabetic wounds by topical administration of adipose tissue-derived stromal cells overexpressing stromal-derived factor-1: biodistribution and engraftment analysis by bioluminescent imaging. Stem Cells Int 2010; 2011: 304562.
33. Lau TT, Wang DA. Stromal cell-derived factor-1 (SDF-1): homing factor for engineered regenerative medicine. Expert Opin Biol Ther 2011; 11: 189-97.
34. Tang JM, Wang JN, Zhang L, et al. VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart. Cardiovasc Res 2011; Epub ahead of print.
35. Lazarus GS, Cooper DM, Knighton DR, et al. Definitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol 1994; 130: 489-93.
36. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-64.
37. Tamama K, Kawasaki H, Kerpedjieva SS, Guan J, Ganju RK, Sen CK. Differential roles of hypoxia inducible factor subunits in multipotential stromal cells under hypoxic condition. J Cell Biochem 2011; 112: 804-17.
38. Schreml S, Szeimies RM, Prantl L, Karrer S, Landthaler M, Babilas P. Oxygen in acute and chronic wound healing. Br J Dermatol 2010; 163: 257-68.
39. Sheffield PJ. Measuring tissue oxygen tension: a review. Undersea Hyperb Med 1998; 25: 179-88.
40. LaVan FB, Hunt TK. Oxygen and wound healing. Clin Plast Surg 1990; 17: 463-72.
41. Knighton DR, Silver IA, Hunt TK. Regulation of wound-healing angiogenesis-effect of oxygen gradients and inspired oxygen concentration. Surgery 1981; 90: 262-70.
42. Sheikh AY, Gibson JJ, Rollins MD, Hopf HW, Hussain Z, Hunt T. Effect of hyperoxia on vascular endothelial growth factor levels in a wound model. Arch Surg 2000; 135: 1293-7.
43. Alonso-Echanove J, Richards C Jr, Horan TC. Supplemental perioperative oxygen to reduce surgicalwound infections. N Engl J Med 2000; 342: 1613.
44. Lindholm C, Bjellerup M, Christensen OB, Zederfeldt B. A demographic survey of leg and foot ulcer patients in a defined population. Acta Derm Venereol 1992; 72: 227-30.
45. Phillips TJ. Chronic cutaneous ulcers: etiology and epidemiology. J Invest Dermatol 1994; 102: 38S-41S.
46. Thom SR, Bhopale VM, Velazquez OC, Goldstein LJ, Thom LH, Buerk DG. Stem cell mobilization by hyperbaric oxygen. Am J Physiol Heart Circ Physiol 2006; 290: H1378-86.
47. Goldstein LJ, Gallagher KA, Bauer SM, et al. Endothelial progenitor cell release into circulation is triggered by hyperoxia-induced increases in bone marrow nitric oxide. Stem Cells 2006; 24: 2309-18.
48. Nagano M, Kimura K, Yamashita T, et al. Hypoxia responsive mesenchymal stem cells derived from human umbilical cord blood are effective for bone repair. Stem Cells Dev 2010; 19: 1195-210.
49. Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 15-29.
50. Vatn M. Mucosal healing: impact on the natural course or therapeutic strategies. Dig Dis 2009; 27: 470-5.
51. McLaren WJ, Anikijenko P, Thomas SG, Delaney PM, King RG. In vivo detection of morphological and microvascular changes of the colon in association with colitis using fiberoptic confocal imaging (FOCI). Dig Dis Sci 2002; 47: 2424-33.
52. Tarnawski A, Coron E, Mosnier JF, et al. In-vivo detection by confocal endomicroscopy of two distinct structural abnormalities in angioarchitecture and increased VP in colonic mucosa of patients with IBD in remission: mechanistic implications. Gastroenterology2009; 136: A112.
53. Cheon JH, Kim WH. Recent advances of endoscopy in inflammatory bowel diseases. Gut Liver 2007; 1: 118-25.
54. Aychek T, Vandoorne K, Brenner O, Jung S, Neeman M. Quantitative analysis of intravenously administered contrast media reveals changes in vascular barrier functions in a murine colitis model. Magn Reson Med 2011; Epub ahead of print.
55. McLaren W, Anikijenko P, Barkla D, Delaney TP, King R. In vivo detection of experimental ulcerative colitis in rats using fiberoptic confocal imaging (FOCI). Dig Dis Sci 2001; 46: 2263-76.
56. McGuckin MA, Eri R, Simms LA, Florin TH, Radford-Smith G. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 2009; 15: 100-13.
57. Taylor CT, Colgan SP. Hypoxia and gastrointestinal disease. J Mol Med 2007; 85: 1295-300.
58. Tolstanova G, Deng XM, French SW, et al. Early endothelial damage and increased colonic vascular permeability in the development of experimental ulcerative colitis in rats and mice. Lab Invest 2011; accepted.
59. Harris NR, Carter PR, Yadav AS, et al. Relationship between inflammation and tissue hypoxia in a mouse model of chronic colitis. Inflamm Bowel Dis 2011; 17: 742-6.
60. Deban L, Correale C, Vetrano S, Malesci A, Danese S. Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades. Am J Pathol 2008; 172: 1457-66.
61. Ferrante M, Pierik M, Henckaerts L, et al. The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 870-8.
62. Klagsbrun M. Regulators of angiogenesis: stimulators, inhibitors, and extracellular matrix. J Cell Biochem 1991; 47: 199-200.
63. Ferrara N, Gerber HP, eCouter J. The biology of VEGF and its receptors. Nat Med 2000; 39: 669-76.
64. Oluleye TS. Diabetic retinopathy: current developments in pathogenesis and management. Afr J Med Med Sci 2010; 39: 199-206.
65. Wang Q, Diao X, Sun J, Chen Z. Stromal cell-derived factor-1 and vascular endothelial growth factor as biomarkers for lymph node metastasis and poor cancer-specific survival in prostate cancer patients after radical prostatectomy. Urol Oncol 2011; Epub ahead of print.
66. Kapsoritakis A, Sfiridaki A, Maltezos E, et al. Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis 2003; 18: 418-22.
67. Scaldaferri F, Vetrano S, Sans M, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009; 136: 585-95.
68. Ferrante M, Pierik M, Henckaerts L, et al. The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 870-8.
69. Sandor Zs, Szabo S, Zagoni T, Tulassay Zs. Differential changes of bFGF and PDGF in human serum and biopsy samples in UC and Crohn's disease. Gastroenterology 1998; 114: A1075.
70. Griga T, Tromm A, Spanger J and May B. Increased serum level of vascular endothelial growth factor in patients with inflammatory bowel disease. Scand J Gastroenterol 1998: 33: 504-8.
71. Griga T, Voigt E, Gretzer B, et al. Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease. Hepato-Gastroenterology 1999; 46: 920-3.
72. Kanazawa S, Tsunoda T, Onuma E, et al. VEGF, basic-FGF, and TGF-beta in Crohn's disease and UC: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol 2001; 96: 822-8.
73. Konno S, Iizuka M, Yukawa M, et al. Altered expression of angiogenic factors in the VEGF-Ets-1 cascades in inflammatory bowel disease. J Gastroenterol 2004; 39: 931-9.
74. Chidlow JH Jr, Shukla D, Grisham MB, Kevil CG. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. Am J Physiol Gastrointest Liver Physiol 2007; 293: G5-G18.
75. Koutroubakis IE, Tsiolakidou G, Karmiris K, Kouroumalis EA. Role of angiogenesis in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 515-23.
76. Deng X, Szabo S, Khomenko T, Jadus MR, Yoshida M. Gene therapy with adenoviral plasmids or naked DNA of vascular endothelial growth factor and platelet-derived growth factor accelerates healing of duodenal ulcer in rats. J Pharmacol Exp Ther 2004; 311: 982-8.
77. Jones MK, Kawanaka H, Baatar D, et al. Gene therapy for gastric ulcers with single local injection of naked DNA encoding VEGF and angiopoietin-1. Gastroenterology 2001; 121: 1040-7.
78. Kusumanto YH, van Weel V, Mulder NH, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther 2006; 17: 683-91.
79. Katoh O, Tauchi H, Kawaishi K, Kimura A, Satow Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 1995; 55: 5687-92.
80. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172: 1535-45.
81. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marmé D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87: 3336-43.
82. Kucia M, Jankowski K, Reca R, et al. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 2004; 35: 233-45.
83. Zheng H, Fu G, Dai T, Huang H. Migration of endothelial progenitor cells mediated by stromal cell-derived factor-1alpha/CXCR4 via PI3K/Akt/eNOS signal transduction pathway. J Cardiovasc Pharmacol 2007; 50: 274-80.
84. Katsuta T, Lim C, Shimoda K, et al. Interleukin-8 and SDF1-alpha mRNA expression in colonic biopsies from patients with inflammatory bowel disease. Am J Gastroenterol 2000; 95: 3157-64.
85. Xia XM, Wang FY, Xu WA, et al. CXCR4 antagonist AMD3100 attenuates colonic damage in mice with experimental colitis. World J Gastroenterol 2010; 16: 2873-80.
86. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-64.
87. Capobianco S, Chennamaneni V, Mittal M, Zhang N, Zhang C. Endothelial progenitor cells as factors in neovascularization and endothelial repair. World J Cardiol 2010; 2: 41120.
88. Masuda J, Mitsuyama K, Yamasaki H, et al. Depletion of endothelial progenitor cells in the peripheral blood of patients with ulcerative colitis. Int J Mol Med 2007; 19: 221-8.
89. Garolla A, D'Incà R, Checchin D, et al. Reduced endothelial progenitor cell number and function in inflammatory bowel disease: a possible link to the pathogenesis. Am J Gastroenterol 2009; 104: 2500-7.
90. Brittan M, Hunt T, Jeffery R, et al. Bone marrow derivation of pericryptal myofibroblasts in the mouse and human small intestine and colon. Gut 2002; 50: 752-7.
91. Okamoto R, Yajima T, Yamazaki M, et al. Damaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract. Nat Med 2002; 9: 1011-7.
92. Danese S, Sans M, de la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006; 130: 2060-73.
93. Sandor Zs, Deng XM, Khomenko T, Tarnawski AS, Szabo S. Altered angiogenic balance in ulcerative colitis: A key to impaired healing. Biochem Biophys Res Commun 2006; 350: 147-50.
94. Tolstanova G, Deng X, Khomenko T, et al. Role of anti-angiogenic factor endostatin in the pathogenesis of experimental ulcerative colitis. Life Sci 2010; 88: 74-81.
95. Hoenig MR, Bianchi C, Rosenzweig A, Sellke FW. Decreased vascular repair and neovascularization with ageing: mechanisms and clinical relevance with an emphasis on hypoxia-inducible factor- 1. Curr Mol Med 2008; 8: 754-67.
96. Hoenig MR, Bianchi C, Sellke FW. Hypoxia inducible factor-1 alpha, endothelial progenitor cells, monocytes, cardiovascular risk, wound healing, cobalt and hydralazine: a unifying hypothesis. Curr Drug Targets 2008; 9: 422-35.
97. Herrinton L J, Liu L, Lewis JD, Griffin PM, and Allison J. Incidence and prevalence of inflammatory bowel disease in Northern California managed care organization, 1996-2002. Am J Gastroenterol 2008; 103: 1998-2006.
98. Chidlow JH Jr, Langston W, Greer JJ, et al. Differential angiogenic regulation of experimental colitis. Am J Pathol 2006; 169: 2014-30.
99. Danese S, et al. Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut 2007; 56: 855-62.
100. Danese S. Inflammation and the mucosal microcirculation in inflammatory bowel disease: the ebb and flow. Curr Opin Gastroenterol 2007; 23: 384-9.
101. Shi M, Liu ZW, Wang FS. Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin Exp Immunol 2011; 164: 1-8.
102. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233-58.
103. Chen L, Deng XM, Xiong XM, Szabo S, Sandor Zs. Intracolonical application of bone marrow-derived stem cells accelerates ulcerative colitis healing in rats: A new alternative to bone marrow transplantation. Gastroenterology 2010; 138: S568-9.
104. Liekens S, Schols D, Hatse S. CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Curr Pharm Des 2010; 16: 3903-20.
105. Ditschkowski M, Einsele H, Schwerdtfeger R, et al. Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation. Transplantation 2003; 75: 1745-7.